Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agile Therapeutics, Inc. - Common Stock (NQ:AGRX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Agile Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
A Look Into Healthcare Sector Value Stocks
Via Benzinga
This Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions Of Women Thanks To A Partnership With Afaxys
Agile Therapeutics, Inc.’s (NASDAQ: AGRX) partnership with Afaxys Pharma is expected to play a key role in propelling the women’ 
Via Benzinga
Agile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of Women
This month, Agile Therapeutics, Inc. (NASDAQ: AGRX) announced partnerships with FPA Women’s Health and 
Via Benzinga
Agile Sees Renewed Hope For Even Broader Adoption Of Its Weekly Birth Control Patch After Biden's Latest Executive Order Expanding Contraceptive Coverage
In June, President Biden issued an Executive Order on Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services. 
Via Benzinga
Why Tattooed Chef Are Trading Lower By 47%; Here Are 20 Stocks Moving Premarket
Gainers Micromobility.com Inc. (NASDAQ: MCOM) shares surged 60% to $0.18 in pre-market trading. micromobility.com recently reported a strategic realignment to strengthen its financial position and... 
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
A Look Into Healthcare Sector Value Stocks
Via Benzinga
H.C. Wainwright Reiterates Buy Rating For Agile Therapeutics (NASDAQ: AGRX), Citing Growing Demand For Twirla, A Weekly Low Dose Birth Control Patch
H.C. Wainwright & Co, reiterated its buy rating on Agile Therapeutics, Inc. (NASDAQ: AGRX) this month, setting a price target of $12 per share. 
Via Benzinga
This Women's Healthcare Company Raised $7.5 Million In A Public Offering And Says It's Targeting $25 To $30 Million Net Revenue By End Of 2023
Agile Therapeutics (NASDAQ: AGRX) announced the closing of its public offering in May. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 32 companies set new 52-week lows. 
Via Benzinga
Agile Therapeutics – This Women's Healthcare Company's "Skinfusion" Technology Sets It Apart From Other Contraceptive Companies
Al Altomari, Chairman & CEO of Agile Therapeutics (NASDAQ: AGRX) was recently interviewed by Benzinga.  
Via Benzinga
Agile Therapeutics: Q1 Earnings Insights
Via Benzinga
Agile Therapeutics Earnings Preview
Via Benzinga
Agile Therapeutics's Return On Capital Employed Insights
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 64 companies achieved new lows for the year. 
Via Benzinga
Why Agile Therapeutics Stock Is Trading Higher Today
Agile Therapeutics Inc (NASDAQ: AGRX) announced an agreement with vitaCare Prescription Services, a wholly owned subsidiary of GoodRx Holdings Inc (NASDAQ: GDRX), to expand patient access and... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Inventiva Shares Are Trading Higher By 24%; Here Are 20 Stocks Moving Premarket
Gainers Cyxtera Technologies, Inc. (NASDAQ: CYXT) shares rose 134.6% to $0.0981 in pre-market trading after dropping 12% on Tuesday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers as investors get ready to trade shares on Wednesday morning! 
Via InvestorPlace
Agile Therapeutics Expects Its Innovative Once-A-Week Birth Control Patch To Drive Revenues Of $25-30 Million In 2023 – What Is The Hype All About?
Women are itching for more birth control options that cater to their unique needs and preferences. While traditional forms of birth control – such as the pill and condoms – have been reliable options... 
Via Benzinga
The Overturning of Roe v. Wade Has Changed The Landscape Of Birth Control; Smaller Companies Are Now An Integral Part Of Care
The invention of birth control in the 1960s revolutionized women's health and their lives. In 2022, the contraceptive market was valued at $8.3 billion and it is projected to grow at a compound annual... 
Via Benzinga
Agile Therapeutics: The CEO Of This Women's Healthcare Company That Recently Saw Revenue Growth Of 33% Speaks To Benzinga
Al Altomari, Chairman & CEO of Agile Therapeutics (NASDAQ: AGRX) was recently a guest on Benzinga’s All Access. 
Via Benzinga
National Instruments, Nutex Health And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Why Agile Therapeutics Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
Gainers ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA) shares rose 82.8% to $2.98 in pre-market trading. ZyVersa Therapeutics recently reported new employment inducement grants under Nasdaq Listing Rule... 
Via Benzinga
Why Kalera Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Innovative Eyewear, Inc. (NASDAQ: LUCY) jumped 164% to $3.86 after the company announced it launched ChatGPT-enabled smart eyewear. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday! 
Via InvestorPlace
Why Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers DiamondHead Holdings Corp. (NASDAQ: DHHC) shares jumped 104.2% to $21.15. DiamondHead entered into convertible note purchase agreement dated March 21, 2023. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Agile Therapeutics: This BioPharma Firm Is Nimbly Solving Unmet Needs For Women
Agile Therapeutics: This BioPharma Firm Is Nimbly Solving Unmet Needs For Women 
Via News Direct
Agile Therapeutics: This BioPharma Firm Is Nimbly Solving Unmet Needs For Women
Al Altomari, Chairman and CEO of Agile Therapeutics Inc (NASDAQ: AGRX), was recently interviewed by Benzinga. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.